Characterization of M1/M2 Tumour-Associated Macrophages (TAMs) and Th1/Th2 Cytokine Profiles in Patients with NSCLC

Cancer Microenvironment

Volumn 9, Issue 1, 2016, Pages 1-11

  Almatroodi, S A ^a,c   McDonald, C F ^b   Darby, I A ^a   Pouniotis, D S ^a  

^a RMIT UNIVERSITY   (Australia)

^b AUSTIN HEALTH   (Australia)

^c QASSIM UNIVERSITY   (Saudi Arabia)

Author keywords

Lung cancer; Lung tissue; M1 macrophages; M2 macrophages; Tumour associated macrophages

Indexed keywords

CD163 ANTIGEN; CD68 ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8;

ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CANCER TISSUE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SQUAMOUS CELL CARCINOMA; TH1 CELL; TH2 CELL; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION;

EID: 84941358498     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-015-0174-x     Document Type: Article

References (52)

1. Shih J-Y, Yuan A, Chen JJ-W, Yang P-C (2006) Tumor-associated macrophage: its role in cancer invasion and metastasis. J Cancer Mol 2(3):101–106
2. Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66(2):605–612. doi:10.1158/0008-5472.CAN-05-4005
3. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23(11):549–555
4. Dirkx AE, Oude Egbrink MG, Wagstaff J, Griffioen AW (2006) Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 80(6):1183–1196, 10.1189/jlb.0905495
5. Lamagna C, Aurrand-Lions M, Imhof BA (2006) Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol 80(4):705–713. doi:10.1189/jlb.1105656
6. Quatromoni JG, Eruslanov E (2012) Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res 4(4):376–389
7. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25(12):677–686
8. Lopez-Gonzalez JS, Avila-Moreno F, Prado-Garcia H, Aguilar-Cazares D, Mandoki JJ, Meneses-Flores M (2007) Lung carcinomas decrease the number of monocytes/macrophages (CD14+ cells) that produce TNF-[alpha]. Clin Immunol 122(3):323–329
9. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P (2009) Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 33(1):118–126. doi:10.1183/09031936.00065708
10. Redente EF, Dwyer-Nield LD, Merrick DT, Raina K, Agarwal R, Pao W, Rice PL, Shroyer KR, Malkinson AM (2010) Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. Am J Pathol 176(6):2972–2985. doi:10.2353/ajpath.2010.090879
11. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O’Neill A, Mier J, Ochoa AC (2005) Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65(8):3044–3048
12. Chang CI, Liao JC, Kuo L (2001) Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res 61(3):1100–1106
13. Biswas SK, Sica A, Lewis CE (2008) Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 180(4):2011–2017
14. Gorrin-Rivas MJ, Arii S, Mori A, Takeda Y, Mizumoto M, Furutani M, Imamura M (2000) Implications of human macrophage metalloelastase and vascular endothelial growth factor gene expression in angiogenesis of hepatocellular carcinoma. Ann Surg 231(1):67–73
15. Edin S, Wikberg ML, Dahlin AM, Rutegard J, Oberg A, Oldenborg PA, Palmqvist R (2012) The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One 7(10), e47045. doi:10.1371/journal.pone.0047045
16. Edin S, Wikberg ML, Oldenborg PA, Palmqvist R (2013) Macrophages: good guys in colorectal cancer. OncoImmunology 2(2), e23038. doi:10.4161/onci.23038
17. Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122(3):787–795. doi:10.1172/jci59643
18. UyBico SJ, Wu CC, Suh RD, Le NH, Brown K, Krishnam MS (2010) Lung cancer staging essentials: the new TNM staging system and potential imaging pitfalls. Radiographics 30(5):1163–1181. doi:10.1148/rg.305095166
19. Welsh TJ, Green RH, Richardson D, Waller DA, O’Byrne KJ, Bradding P (2005) Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 23(35):8959–8967. doi:10.1200/jco.2005.01.4910
20. Wang R, Zhang J, Chen S, Lu M, Luo X, Yao S, Liu S, Qin Y, Chen H (2011) Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer (Amsterdam, Netherlands) 74(2):188–196. doi:10.1016/j.lungcan.2011.04.009
21. Takanami I, Takeuchi K, Kodaira S (1999) Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology 57(2):138–142
22. Ohtaki Y, Ishii G, Nagai K, Ashimine S, Kuwata T, Hishida T, Nishimura M, Yoshida J, Takeyoshi I, Ochiai A (2010) Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 5(10):1507–1515. doi:10.1097/JTO.0b013e3181eba692
23. Zeni E, Mazzetti L, Miotto D, Lo Cascio N, Maestrelli P, Querzoli P, Pedriali M, De Rosa E, Fabbri LM, Mapp CE, Boschetto P (2007) Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J 30(4):627–632. doi:10.1183/09031936.00129306
24. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P (2011) The tissue microlocalisation and cellular expression of CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 is correlated to clinical outcome in NSCLC. PLoS One 6(7), e21874. doi:10.1371/journal.pone.0021874
25. Bingle L, Brown N, Lewis C (2002) The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 196(3):254–265
26. Toomey D, Smyth G, Condron C, Kelly J, Byrne AM, Kay E, Conroy RM, Broe P, Bouchier-Hayes D (2003) Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: No association with prognosis identified in 3-year follow-up. Int J Cancer J Int Cancer 103(3):408–412. doi:10.1002/ijc.10836
27. Tataroglu C, Kargi A, Ozkal S, Esrefoglu N, Akkoclu A (2004) Association of macrophages, mast cells and eosinophil leukocytes with angiogenesis and tumor stage in non-small cell lung carcinomas (NSCLC). Lung Cancer (Amsterdam, Netherlands) 43(1):47–54
28. Ma J, Liu L, Che G, Yu N, Dai F, You Z (2010) The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 10:112. doi:10.1186/1471-2407-10-112
29. Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, Vago L, Nebuloni M, Mantovani A, Sica A (2006) A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107(5):2112–2122. doi:10.1182/blood-2005-01-0428
30. Dinapoli MR, Calderon CL, Lopez DM (1996) The altered tumoricidal capacity of macrophages isolated from tumor-bearing mice is related to reduce expression of the inducible nitric oxide synthase gene. J Exp Med 183(4):1323–1329
31. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 26(21):3543–3551. doi:10.1200/jco.2007.15.0375
32. Zhang B, Yao G, Zhang Y, Gao J, Yang B, Rao Z, Gao J (2011) M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics 66(11):1879–1886. doi:10.1590/S1807-59322011001100006
33. Chung FT, Lee KY, Wang CW, Heh CC, Chan YF, Chen HW, Kuo CH, Feng PH, Lin TY, Wang CH, Chou CL, Chen HC, Lin SM, Kuo HP (2012) Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int J Cancer J Int Cancer 131(3):E227–E235. doi:10.1002/ijc.27403
34. Belardelli F, Ferrantini M (2002) Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol 23(4):201–208
35. Matanic D, Beg-Zec Z, Stojanovic D, Matakoric N, Flego V, Milevoj-Ribic F (2003) Cytokines in patients with lung cancer. Scand J Immunol 57(2):173–178
36. Romagnani S (1995) Biology of human TH1 and TH2 cells. J Clin Immunol 15(3):121–129
37. Romagnani S (1996) Th1 and Th2 in human diseases. Clin Immunol Immunopathol 80(3 Pt 1):225–235
38. Gursel G, Gokcora N, Elbeg S, Samurkasoglu B, Ekim N (1995) Tumor necrosis factor-alpha (TNF-alpha) in pleural fluids. Tuber Lung Dis 76(4):370–371
39. Brooks N, Stojanovska L, Grant P, Apostolopoulos V, McDonald CF, Pouniotis DS (2012) Characterization of blood monocyte phenotype in patients with endometrial cancer. Int J Gynecol Cancer 22(9):1500–1508. doi:10.1097/IGC.0b013e3182249273
40. Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M (2010) Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell 17(1):89–97. doi:10.1016/j.ccr.2009.12.008
41. Yi H, Cho HJ, Cho SM, Jo K, Park JA, Kim NH, Amidon GL, Kim JS, Shin HC (2012) Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells. Int J Oncol 41(1):310–316. doi:10.3892/ijo.2012.1447
42. De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A, Catalano G (1998) Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 5(3):649–652
43. Crohns M, Saarelainen S, Laine S, Poussa T, Alho H, Kellokumpu-Lehtinen P (2010) Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy—association of interleukin-8 and VEGF with survival. Cytokine 50(1):30–36. doi:10.1016/j.cyto.2009.11.017
44. Juarez E, Nunez C, Sada E, Ellner JJ, Schwander SK, Torres M (2010) Differential expression of toll-like receptors on human alveolar macrophages and autologous peripheral monocytes. Respir Res 11:2
45. Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14(21):6735–6741. doi:10.1158/1078-0432.CCR-07-4843
46. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25(3):387–408. doi:10.1007/s10555-006-9004-4
47. Chen JJ, Yao PL, Yuan A, Hong TM, Shun CT, Kuo ML, Lee YC, Yang PC (2003) Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 9(2):729–737
48. Millar HJ, Nemeth JA, McCabe FL, Pikounis B, Wickstrom E (2008) Circulating human interleukin-8 as an indicator of cancer progression in a nude rat orthotopic human non-small cell lung carcinoma model. Cancer Epidemiol Biomarkers Prev 17(8):2180–2187. doi:10.1158/1055-9965.EPI-07-2915
49. Culig Z (2011) Cytokine disbalance in common human cancers. Biochim Biophys Acta 1813(2):308–314. doi:10.1016/j.bbamcr.2010.12.010
50. Albulescu R, Codrici E, Popescu ID, Mihai S, Necula LG, Petrescu D, Teodoru M, Tanase CP (2013) Cytokine patterns in brain tumour progression. Mediat Inflamm 2013:7. doi:10.1155/2013/979748
51. Pellegrini P, Contasta I, Del Beato T, Ciccone F, Berghella AM (2011) Gender-specific cytokine pathways, targets, and biomarkers for the switch from health to adenoma and colorectal cancer. Clin Dev Immunol 819724. doi:10.1155/2011/819724
52. Schuurs AH, Verheul HA (1990) Effects of gender and sex steroids on the immune response. J Steroid Biochem 35(2):157–172